Health Care·Pharmaceuticals·$153.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.34 | N/A | -43.14% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.34 | N/A | -43.14% |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management maintained a neutral tone during the call, highlighting the lack of specific revenue insights. They did not provide any forward guidance.
Management did not provide specific insights on revenue performance.
No guidance was offered for future quarters.
Pfizer's earnings report shows a significant miss on EPS, which may raise concerns among investors about the company's profitability. Despite this, the stock reaction remained flat, indicating that investors may have anticipated the miss or are waiting for more information. The lack of revenue data and guidance leaves uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TEXAS INSTRS INC
Oct 20, 2008